Pharma BD Deal Intelligence
Merck and Seattle Genetics ink two new strategic cancer collaborations covering ladiratuzumab vedotin ADC and TUKYSA regional licensing deal.
Seattle Genetics and Merck announce two strategic oncology collaborations including $600M upfront plus $1B equity for ladiratuzumab vedotin co-development.
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Merck and Seattle Genetics (now Seagen) formed two strategic oncology collaborations. Merck paid $600M upfront and made a $1B equity investment for global co-development/co-commercialization of ladiratuzumab vedotin (LIV-1 targeting ADC), with up to $2.6B in milestones. Separately, Merck licensed TUKYSA (tucatinib) for HER2+ cancers in Asia, Middle East, LatAm.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Seagen Inc. (this deal) | 2020 | $4.2B | 29 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2020 deals · Merck & Co. Inc. deals · Oncology deals